Prevention and treatment of osteoporosis in women

Menopause International

Volumn 13, Issue 4, 2007, Pages 178-181

  al Azzawi, Farook ^a   Barlow, David ^a   Hillard, Tim ^a   Studd, John ^a   Williamson, Jenny ^a   Rees, Margaret ^a  

^a NONE

Author keywords

BISPHOSPHONATE; CALCIUM AND VITAMIN D; ESTROGEN; FRACTURE; OSTEOPOROSIS

Indexed keywords

VITAMIN D; ALENDRONIC ACID; ARZOXIFENE; BAZEDOXIFENE; CALCITONIN; CALCITRIOL; CALCIUM; CALCIUM CARBONATE; CITRATE CALCIUM; CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; LASOFOXIFENE; OSPEMIFENE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; TAMOXIFEN;

CALCIUM INTAKE; DRUG EFFECT; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FEMALE; FRACTURE; HIP FRACTURE; HUMAN; MENOPAUSE; METHODOLOGY; OSTEOPOROSIS; PRACTICE GUIDELINE; REVIEW; WOMEN'S HEALTH; BONE MASS; BONE MINERAL; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SAFETY; EXERCISE; FRACTURE REDUCTION; FRAGILITY FRACTURE; HEART PROTECTION; HORMONE SUBSTITUTION; HOT FLUSH; MUSCLE CRAMP; OVARY INSUFFICIENCY; PROTECTIVE EQUIPMENT; RISK BENEFIT ANALYSIS; SUN EXPOSURE; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION;

CALCIUM, DIETARY; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; FRACTURES, BONE; GUIDELINES AS TOPIC; HIP FRACTURES; HUMANS; MENOPAUSE; OSTEOPOROSIS; VITAMIN D; WOMEN'S HEALTH;

EID: 41949101715     PISSN: 17540453     EISSN: None     Source Type: Journal    
DOI: 10.1258/175404507783004168     Document Type: Article

References (12)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001;285:785-95
2. Johnell O, Kanis J. Epidemiology of osteoporotic fractures. Osteoporos Int 2005;16 (Suppl 2):S3-7
3. Cauley JA, Robbins J, Chen Z, et al., Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA 2003;290:1729-38
4. Ettinger B, Ensrud KE, Wallace R, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. Obstet Gynecol 2004;104:443-51
5. Bagger YZ, Tankó LB, Alexandersen P, et al. Two to three years of hormone replacement treatment in healthy women have longterm preventive effects on bone mass and osteoporotic fractures: the PERF study. Bone 2004;34:728-35
6. Committee on Safety of Medicines. Further advice on safety of HRT: risk:benefit unfavourable for first-line use in prevention of osteoporosis. CEM/CMO/2003/19. See www.mhra.gov.uk (last accessed October 2007)
7. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77
8. Pitkin J, Rees MC, Gray S, et al. Management of premature menopause. Menopause Int 2007;13:44-5
9. Poole KES, Compston JE. Osteoporosis and its management. BMJ 2006;333:1251-6
10. Basu N, Reid DM. Bisphosphonate-associated osteonecrosis of the jaw. Menopause Int 2007;13:56-9
11. Black DM, Schwartz AV, Ensrud KE, et al., FLEX Research Group. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927-38
12. Silverman SL, Watts NB, Delmas PD, Lange JL, Lindsay R. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study. Osteoporos Int 2007;18:25-34